Comorbid ASD in youth with ADHD is linked to greater healthcare utilization and distinct medication treatment patterns.

Viloxazine extended-release shows promise for treating adults with ADHD who also experience symptoms of depression and anxiety.

Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced ...

Atomoxetine, a selective norepinephrine reuptake inhibitor (SNRI), may improve outcomes for patients with both attention-deficit/hyperactivity disorder (ADHD) and ...

Otsuka’s ADHD drug centanafadine is currently under review by the US FDA, with a PDUFA date of 24 July 2026.

Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists Using data from the Surveillance, Epidemiology, and End ...

Lung cancer patients with comorbid conditions such as chronic obstructive pulmonary disease, diabetes, or congestive heart failure have a higher risk of death than lung cancer patients without ...

Although erectile dysfunction (ED) has been considered a complication of other medical conditions, clinicians and researchers suggest that ED may serve as a clinical marker of vascular health. This ...